BXL 746

Drug Profile

BXL 746

Alternative Names: BXL746

Latest Information Update: 30 Dec 2011

Price : $50

At a glance

  • Originator Roche
  • Developer Cosmo Pharmaceuticals; Roche
  • Class Vitamin D analogues
  • Mechanism of Action Vitamin D3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Post-surgical adhesions
  • Discontinued Inflammatory bowel diseases

Most Recent Events

  • 12 Mar 2010 BioXell SpA has been acquired and merged into Cosmo Pharmaceuticals
  • 30 Jun 2007 Phase-I clinical trials in Post-surgical adhesions in Italy (Intraperitoneal)
  • 16 Jan 2007 Preclinical trials in Post-surgical adhesions in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top